Goldstein L B, Coviello A
Neurology Research Laboratory, Durham Department of Veterans' Affairs Medical Center, NC 27705.
Brain Res. 1992 May 15;580(1-2):129-36. doi: 10.1016/0006-8993(92)90936-4.
Although treatment with N-methyl-D-aspartate (NMDA) receptor antagonists reduce neuronal loss after cerebral infarction and brain trauma in laboratory animals, there is little data concerning the effects of these drugs on behavioral recovery. Because NMDA receptor antagonists impede certain kinds of learning, and because motor recovery after sensorimotor cortex injury in the rat is dependent on post-lesion experience, we hypothesized that treatment with MK-801 after focal brain injury would be detrimental. Groups of rats were first trained to traverse a narrow elevated beam and then subjected a right sensorimotor cortex suction-ablation lesion. In the first experiment, 24 h later, each rat received a single dose of either saline or the NMDA receptor antagonist MK-801 (0.5, 1.0, or 2.0 mg/kg). Beam-walking recovery was measured over the next 12 days. In a second experiment, rats were given 3 doses of MK-801 (0.5 mg/kg) at 24 h intervals beginning 24 h after cortex injury. In a third experiment, lesioned and sham-operated rats were allowed to recover for 12 days and then given MK-801 (0.5 mg/kg). Despite obvious behavioral effects of the drug, there was no overall difference in beam-walking performances among the treatment groups in any of the experiments. If 're-learning' is involved in motor recovery after cortex injury, the present results suggest that the process is not susceptible to permanent disruption by the early or late administration of an NMDA receptor antagonist.
尽管在实验动物中,用N-甲基-D-天冬氨酸(NMDA)受体拮抗剂治疗可减少脑梗死后和脑外伤后的神经元损失,但关于这些药物对行为恢复影响的数据却很少。由于NMDA受体拮抗剂会妨碍某些类型的学习,并且由于大鼠感觉运动皮层损伤后的运动恢复依赖于损伤后的经验,我们推测局灶性脑损伤后用MK-801治疗会产生不利影响。将大鼠分组,首先训练它们穿过狭窄的高架横梁,然后对右侧感觉运动皮层进行抽吸消融损伤。在第一个实验中,24小时后,每只大鼠接受单剂量的生理盐水或NMDA受体拮抗剂MK-801(0.5、1.0或2.0mg/kg)。在接下来的12天内测量横梁行走恢复情况。在第二个实验中,大鼠在皮层损伤后24小时开始,每隔24小时给予3剂MK-801(0.5mg/kg)。在第三个实验中,对损伤和假手术的大鼠进行12天的恢复,然后给予MK-801(0.5mg/kg)。尽管该药物有明显的行为学效应,但在任何实验中,各治疗组之间的横梁行走表现均无总体差异。如果“重新学习”参与了皮层损伤后的运动恢复,那么目前的结果表明,该过程不易受到早期或晚期给予NMDA受体拮抗剂的永久性干扰。